Why the study?
Does genetic or pharmacological reduction of PAI-1 improve aging-related cardiovascular pathophysiology in mouse models?
Does genetic or pharmacological reduction of PAI-1 improve aging-related cardiovascular pathophysiology in mouse models?
Answers are grounded in this paper and cite their sources.
Genetic or pharmacological reduction of PAI-1 protects against and reverses aging-related cardiovascular pathophysiology in mouse models, suggesting a potential therapeutic target for vascular aging.
Background: Plasminogen Activator Inhibitor-1 (PAI-1) plays a crucial role in age-related cardiovascular diseases (CVD). We investigate the effects of PAI-1 reduction on cardiovascular physiology using genetically engineered mouse models. Methods: The study utilized a novel mouse line with a dinucleotide duplication mutation in Serpine1 exon 4. L-NAME treatment was used to model aging-related vascular stiffening on heterozygous mutated mice ( Serpine1 TA700/+ ). Cardiovascular physiology was assessed through measurements of systolic blood pressure, diastolic function, and aortic pulse wave velocity. We used a mouse model overexpressing the stabilized human PAI-1 protein and assessed physiological changes with chronological age. Bulk and single-cell RNA sequencing of aortic tissue was performed to identify genetic candidates for protection against aging-like pathophysiology. Lastly, PAI-1 inhibitor TM5614 was used to test the reversal of L-NAME-induced pathophysiology. Results: Serpine1 TA700/+ mice exhibited a 20% longer overall survival compared to controls. These mice also showed attenuated increases in SBP, E/e', and PWV following L-NAME treatment. Conversely, mice overexpressing stabilized human PAI-1 displayed exacerbated cardiovascular pathophysiology. Bulk and single-cell RNA sequencing revealed reduced expression of Ccn1, Npnt, and Itgb1 in Serpine1 TA700/+ mice, suggesting potential mechanisms for vascular protection. Pharmacological inhibition of PAI-1 with TM5614 reversed L-NAME-induced increases in PWV. Conclusion: Genetic reduction of PAI-1 protects against aging-related cardiovascular pathophysiology, while PAI-1 overexpression exacerbates these effects. Pharmacological inhibition of PAI-1 reverses pre-existing aging-related cardiovascular pathology, highlighting its potential as a therapeutic strategy for combating cardiovascular aging and related pathologies.
No takes yet. Share an insight, caveat, or question.
Khoddammohammadi et al. (2025) studied Age-related cardiovascular diseases. Genetic reduction of PAI-1 (Serpine1 TA700/+) or pharmacological inhibition (TM5614) vs. Controls was evaluated on Overall survival and cardiovascular physiology (SBP, E/e', PWV).
Synapse has enriched 10 related papers. Consider them for comparative context: